Physicians Experience with SGLT- 2 Inhibitors In Type 2 Diabetic Patients
DOI:
https://doi.org/10.21649/akemu.v31i3.5752Keywords:
SGLT-2 inhibitors, Diabetes Mellitus, Type 2, perception, physiciansAbstract
Background: Approximately, 104 (55%) physicians reported hypertension (HTN), obesity, chronic kidney disease (CKD) and hyperuricemia as the most prevalent comorbidities in diabetic patients.
Objectives: This study investigates the experience of Pakistani physicians regarding the use of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors in the management of Type 2 Diabetes (T2D).
This cross-sectional survey study was conducted from 1st October to December 31st, 2023, enrolled 189 physicians.
Methods: The data was collected by self-administered structured questionnaire which was distributed among physicians across various specialties involved in diabetes care, assessing their views on the efficacy, safety, and economic considerations of SGLT2 inhibitors.
Results: Approximately, 104 (55%) physicians reported hypertension (HTN), obesity, chronic kidney disease (CKD) and hyperuricemia as the most prevalent comorbidities in diabetic patients. Empagliflozin was the most prescribed among SGLT-2 inhibitor in patients with heart failure. Approximately, 50% of the physicians advise SGLT-2 inhibitor frequently to their patients. Approximately, 81% of the physicians considered efficacious medicine with cost- benefits for their patients and also 89% of them agreed that the cost and quantity of daily diabetes medications impact a patient's overall diabetes management.
Conclusion: The study emphasizes the importance of addressing these economic challenges to enhance the accessibility and utilization of SGLT2 inhibitors, potentially improving health outcomes for patients with T2D. By highlighting physicians' perspectives, this research contributes to the ongoing conversation on optimizing diabetes treatment in Pakistan.
References
1. Azeem S, Khan U, Liaquat A. The increasing rate of diabetes in Pakistan: A silent killer. Ann Med Surg (Lond). 2022;79:103901. doi: 10.1016/j.amsu. 2022. 103901.
2. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Invest. 2014;5(3):265-75. doi: 10. 1111/ jdi.12214.
3. Scheen AJ. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf. 2015; 14(12):1879-904.doi:10.1517/14740338.2015. 1100167.
4. Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383 (15):1436-46. doi:10.1056/NEJMoa2024816
5. Lee G, Oh SW, Hwang SS, Yoon JW, Kang S, Joh HK et al. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and mor- bidity: a network meta-analysis. PloS one. 2017; 12 (5): 0177646. doi.org/10.1371/journal.pone.0177646
6. Min SH, Yoon JH, Hahn S, Cho YM. Comparison bet- ween SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta‐analysis. Diabetes/ Metabolism Research and Reviews. 2017;33(1): 2818. doi.org/10.1002/dmrr.2818
7. Das B, Sheikh A, Ahmed B, Islam N. Clinical outcomes of Sodium-glucose cotransporter-2 inhibitors in patients with Type 2 Diabetes Mellitus: An observational study from Pakistan. Pak J Med Sci. 2021;37(5):1342. doi: 10.12669/pjms.37.5.3901
8. Pawaskar M, Bilir SP, Kowal S, Gonzalez C, Rajpathak S, Davies G. Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes. Am J Manag Care. 2019;25(5):231-8.
9. Rabizadeh S, Nakhjavani M, Esteghamati A. Cardio- vascular and renal benefits of SGLT2 inhibitors: A narrative review. Int J Endocrinol Metab. 2019; 17(2): e84353. doi: 10.5812/ijem.84353.
10. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2024." Diabetes Care. 2024;47(1):158-78. doi: 10.2337/dc24-S009.
11. Milder TY, Stocker SL, Abdel Shaheed C, McGrath- Cadell L, Samocha-Bonet D, Greenfield JR, et al. Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: A systematic review and meta-analysis. J Clin Med. 2019;8(1):45. doi: 10. 3390/ jcm8010045.
12. Liang B, Gu N. Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials. Int J Med Sci. 2022; 19(7): 1118-21. doi: 10.7150/ijms.72772.
13. Khunti K, Jabbour S, Cos X, Mudaliar S, Mende C, Bonaca M, et al. Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice. Diabetes Obes Metab. 2022;24(7):1187-96. doi: 10. 1111/dom.1468.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Annals of King Edward Medical University
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments publications@kemu.edu.pk